Solventum (NYSE:SOLV) Upgraded to “Hold” at BMO Capital Markets

Solventum (NYSE:SOLV) was upgraded by equities researchers at BMO Capital Markets to a “hold” rating in a report released on Wednesday,Zacks.com reports.

SOLV has been the subject of several other research reports. BTIG Research reaffirmed a “buy” rating and set a $89.00 target price on shares of Solventum in a research note on Wednesday, May 6th. UBS Group downgraded shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Thursday, May 14th. Piper Sandler decreased their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Weiss Ratings cut shares of Solventum from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, June 26th. Finally, Rothschild & Co Redburn started coverage on shares of Solventum in a report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Solventum currently has an average rating of “Hold” and a consensus price target of $83.50.

Solventum Stock Performance

Shares of Solventum stock opened at $76.02 on Wednesday. The firm has a market cap of $13.17 billion, a PE ratio of 9.32, a price-to-earnings-growth ratio of 1.16 and a beta of 0.66. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. Solventum has a 52 week low of $62.38 and a 52 week high of $88.20. The business’s fifty day simple moving average is $76.04 and its 200-day simple moving average is $74.30.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company’s quarterly revenue was down 3.0% on a year-over-year basis. During the same period last year, the company earned $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities analysts forecast that Solventum will post 6.58 earnings per share for the current year.

Institutional Trading of Solventum

A number of large investors have recently modified their holdings of SOLV. Hilltop National Bank grew its stake in Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after purchasing an additional 129 shares in the last quarter. CrossGen Wealth LLC purchased a new position in shares of Solventum in the 4th quarter valued at about $25,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Solventum during the 3rd quarter worth about $25,000. JNBA Financial Advisors lifted its stake in Solventum by 205.4% during the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after purchasing an additional 228 shares during the last quarter. Finally, CYBER HORNET ETFs LLC acquired a new position in Solventum in the second quarter valued at approximately $28,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.